US $260 million investment in COPD drugs of theravance

Source: Biovalley 2015-02-03 February 3, 2015 - the generic giant mylan company recently announced that it has reached a cooperation agreement with the famous respiratory medicine developer theravance biology company to jointly develop the COPD drug td-4208 of theravance company in clinical phase II And mylan paid as much as $265 million Under the agreement, mylan will pay terravance $15 million in cash plus $30 million in injected capital There are also milestone funding of up to $220 million In exchange, mylan will share the copyright of the muscarinic antagonists Recently, td-4208 has completed the second phase of clinical research and obtained satisfactory data, theravance said At present, the company is preparing for the third phase clinical research At present, similar drugs on the market, such as Spiriva of bringer Ingelheim company, are mostly administered by hand-held devices, which brings inconvenience to many COPD patients According to the survey, more than 9% of COPD patients in the United States need or are willing to choose drugs for spraying Once approved, td-4208 will be the first inhaled drug of the same type on the market, and will contribute to the development of COPD combination therapy in the future, theravance said At the same time, it is also the largest investment transaction of theravance in recent two years In addition to td-4208, the company has also developed td-1211 for the treatment of opioid drug gastrointestinal side effects, td-9855 for the treatment of chronic pain, td-1792 for the treatment of bacterial infection and td-5108 for the treatment of gastroparesis However, it is worth noting that the transaction between Theravance and the company is only related to aerosol type TD-4208 The company still maintains a global patent for quantitative inhalation inhalers and dry powder inhaled COPD drugs